ID   XYLT1_HUMAN             Reviewed;         959 AA.
AC   Q86Y38; Q9H1B6;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   10-MAY-2017, entry version 113.
DE   RecName: Full=Xylosyltransferase 1;
DE            EC=2.4.2.26 {ECO:0000269|PubMed:15461586};
DE   AltName: Full=Peptide O-xylosyltransferase 1;
DE   AltName: Full=Xylosyltransferase I;
DE            Short=XT-I;
DE            Short=XylT-I;
GN   Name=XYLT1; Synonyms=XT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DISULFIDE BONDS, COFACTOR,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND
RP   MUTAGENESIS OF CYS-257; CYS-276; CYS-285; CYS-301; CYS-471; CYS-542;
RP   CYS-561; CYS-563; CYS-572; CYS-574; CYS-675; CYS-920; CYS-927 AND
RP   CYS-933.
RX   PubMed=15461586; DOI=10.1042/BJ20041206;
RA   Mueller S., Schoettler M., Schoen S., Prante C., Brinkmann T.,
RA   Kuhn J., Goetting C., Kleesiek K.;
RT   "Human xylosyltransferase I: functional and biochemical
RT   characterization of cysteine residues required for enzymic activity.";
RL   Biochem. J. 386:227-236(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 133-959, AND TISSUE SPECIFICITY.
RX   PubMed=11099377; DOI=10.1006/jmbi.2000.4261;
RA   Goetting C., Kuhn J., Zahn R., Brinkmann T., Kleesiek K.;
RT   "Molecular cloning and expression of human UDP-D-xylose:proteoglycan
RT   core protein beta-D-xylosyltransferase and its first isoform XT-II.";
RL   J. Mol. Biol. 304:517-528(2000).
RN   [3]
RP   PROTEIN SEQUENCE OF 159-171; 185-202; 289-296; 444-449; 593-598;
RP   727-748 AND 948-959, AND GLYCOSYLATION.
RX   PubMed=11087729; DOI=10.1074/jbc.M005111200;
RA   Kuhn J., Goetting C., Schnoelzer M., Kempf T., Brinkmann T.,
RA   Kleesiek K.;
RT   "First isolation of human UDP-D-xylose: proteoglycan core protein
RT   beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma
RT   cells.";
RL   J. Biol. Chem. 276:4940-4947(2001).
RN   [4]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10383739; DOI=10.1046/j.1523-1747.1999.00590.x;
RA   Goetting C., Sollberg S., Kuhn J., Weilke C., Huerkamp C.,
RA   Brinkmann T., Krieg T., Kleesiek K.;
RT   "Serum xylosyltransferase: a new biochemical marker of the sclerotic
RT   process in systemic sclerosis.";
RL   J. Invest. Dermatol. 112:919-924(1999).
RN   [5]
RP   REDUCED ACTIVITY IN SEMINAL PLASMA.
RX   PubMed=11814476; DOI=10.1016/S0009-8981(01)00793-8;
RA   Goetting C., Kuhn J., Brinkmann T., Kleesiek K.;
RT   "Xylosyltransferase activity in seminal plasma of infertile men.";
RL   Clin. Chim. Acta 317:199-202(2002).
RN   [6]
RP   BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, AND MUTAGENESIS OF ASP-314;
RP   ASP-316; ASP-745; TRP-746 AND ASP-747.
RX   PubMed=15294915; DOI=10.1074/jbc.M401340200;
RA   Goetting C., Mueller S., Schoettler M., Schoen S., Prante C.,
RA   Brinkmann T., Kuhn J., Kleesiek K.;
RT   "Analysis of the DXD motifs in human xylosyltransferase I required for
RT   enzyme activity.";
RL   J. Biol. Chem. 279:42566-42573(2004).
RN   [7]
RP   INVOLVEMENT IN PXE, SUBCELLULAR LOCATION, VARIANT PXE SER-115, AND
RP   VARIANTS TRP-406 AND MET-665.
RX   PubMed=16571645; DOI=10.1136/jmg.2006.040972;
RA   Schon S., Schulz V., Prante C., Hendig D., Szliska C., Kuhn J.,
RA   Kleesiek K., Gotting C.;
RT   "Polymorphisms in the xylosyltransferase genes cause higher serum XT-I
RT   activity in patients with pseudoxanthoma elasticum (PXE) and are
RT   involved in a severe disease course.";
RL   J. Med. Genet. 43:745-749(2006).
RN   [8]
RP   VARIANT DBQD2 CYS-598.
RX   PubMed=24581741; DOI=10.1016/j.ajhg.2014.01.020;
RA   Bui C., Huber C., Tuysuz B., Alanay Y., Bole-Feysot C., Leroy J.G.,
RA   Mortier G., Nitschke P., Munnich A., Cormier-Daire V.;
RT   "XYLT1 mutations in Desbuquois dysplasia type 2.";
RL   Am. J. Hum. Genet. 94:405-414(2014).
RN   [9]
RP   VARIANT DBQD2 TRP-481.
RX   PubMed=23982343; DOI=10.1007/s00439-013-1351-y;
RA   Schreml J., Durmaz B., Cogulu O., Keupp K., Beleggia F., Pohl E.,
RA   Milz E., Coker M., Ucar S.K., Nurnberg G., Nurnberg P., Kuhn J.,
RA   Ozkinay F.;
RT   "The missing 'link': an autosomal recessive short stature syndrome
RT   caused by a hypofunctional XYLT1 mutation.";
RL   Hum. Genet. 133:29-39(2014).
CC   -!- FUNCTION: Catalyzes the first step in biosynthesis of
CC       glycosaminoglycan. Transfers D-xylose from UDP-D-xylose to
CC       specific serine residues of the core protein. Initial enzyme in
CC       the biosynthesis of chondroitin sulfate and dermatan sulfate
CC       proteoglycans in fibroblasts and chondrocytes.
CC       {ECO:0000269|PubMed:15461586}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-xylose + [protein]-L-serine = UDP
CC       + [protein]-3-O-(beta-D-xylosyl)-L-serine.
CC       {ECO:0000269|PubMed:15461586}.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000269|PubMed:15294915,
CC         ECO:0000269|PubMed:15461586};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.9 uM for recombinant bikunin {ECO:0000269|PubMed:15294915,
CC         ECO:0000269|PubMed:15461586};
CC         Vmax=764 pmol/h/mg enzyme with recombinant bikunin as substrate
CC         {ECO:0000269|PubMed:15294915, ECO:0000269|PubMed:15461586};
CC   -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis.
CC   -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:15461586}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250}; Single-pass type II membrane protein {ECO:0000250}.
CC       Golgi apparatus membrane {ECO:0000269|PubMed:16571645}; Single-
CC       pass type II membrane protein {ECO:0000250}. Secreted
CC       {ECO:0000305|PubMed:10383739}. Note=Some fraction is also found in
CC       the extracellular space together with chondroitin sulfate
CC       proteoglycans, suggesting that it can be secreted.
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed at higher level in
CC       placenta, kidney and pancreas. Weakly expressed in skeletal
CC       muscle. {ECO:0000269|PubMed:11099377}.
CC   -!- PTM: Contains 7 disulfide bonds.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:11087729}.
CC   -!- DISEASE: Desbuquois dysplasia 2 (DBQD2) [MIM:615777]: A
CC       chondrodysplasia characterized by severe prenatal and postnatal
CC       growth retardation (less than -5 SD), joint laxity, short
CC       extremities, progressive scoliosis, round face, midface
CC       hypoplasia, prominent bulging eyes. The main radiologic features
CC       are short long bones with metaphyseal splay, a 'Swedish key'
CC       appearance of the proximal femur (exaggerated trochanter), and
CC       advance carpal and tarsal bone age. Two forms of Desbuquois
CC       dysplasia are distinguished on the basis of the presence or
CC       absence of characteristic hand anomalies: an extra ossification
CC       center distal to the second metacarpal, delta phalanx, bifid
CC       distal thumb phalanx, and phalangeal dislocations.
CC       {ECO:0000269|PubMed:23982343, ECO:0000269|PubMed:24581741}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Pseudoxanthoma elasticum (PXE) [MIM:264800]: A
CC       multisystem disorder characterized by accumulation of mineralized
CC       and fragmented elastic fibers in the skin, vascular walls, and
CC       Burch membrane in the eye. Clinically, patients exhibit
CC       characteristic lesions of the posterior segment of the eye
CC       including peau d'orange, angioid streaks, and choroidal
CC       neovascularizations, of the skin including soft, ivory colored
CC       papules in a reticular pattern that predominantly affect the neck
CC       and large flexor surfaces, and of the cardiovascular system with
CC       peripheral and coronary arterial occlusive disease as well as
CC       gastrointestinal bleedings. {ECO:0000269|PubMed:16571645}.
CC       Note=The gene represented in this entry acts as a disease
CC       modifier.
CC   -!- MISCELLANEOUS: Activity is strongly reduced in seminal plasma of
CC       unfertile men.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 14 family. XylT
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ539163; CAD62248.1; -; mRNA.
DR   EMBL; AJ277441; CAC16787.1; -; mRNA.
DR   CCDS; CCDS10569.1; -.
DR   RefSeq; NP_071449.1; NM_022166.3.
DR   UniGene; Hs.22907; -.
DR   ProteinModelPortal; Q86Y38; -.
DR   BioGrid; 122080; 3.
DR   IntAct; Q86Y38; 2.
DR   STRING; 9606.ENSP00000261381; -.
DR   CAZy; GT14; Glycosyltransferase Family 14.
DR   iPTMnet; Q86Y38; -.
DR   PhosphoSitePlus; Q86Y38; -.
DR   BioMuta; XYLT1; -.
DR   DMDM; 71164803; -.
DR   EPD; Q86Y38; -.
DR   MaxQB; Q86Y38; -.
DR   PaxDb; Q86Y38; -.
DR   PeptideAtlas; Q86Y38; -.
DR   PRIDE; Q86Y38; -.
DR   Ensembl; ENST00000261381; ENSP00000261381; ENSG00000103489.
DR   GeneID; 64131; -.
DR   KEGG; hsa:64131; -.
DR   UCSC; uc002dfa.4; human.
DR   CTD; 64131; -.
DR   DisGeNET; 64131; -.
DR   GeneCards; XYLT1; -.
DR   HGNC; HGNC:15516; XYLT1.
DR   HPA; HPA007478; -.
DR   HPA; HPA007966; -.
DR   MalaCards; XYLT1; -.
DR   MIM; 264800; phenotype.
DR   MIM; 608124; gene.
DR   MIM; 615777; phenotype.
DR   neXtProt; NX_Q86Y38; -.
DR   OpenTargets; ENSG00000103489; -.
DR   Orphanet; 1425; Desbuquois syndrome.
DR   Orphanet; 370930; XYLT1-CDG.
DR   PharmGKB; PA37973; -.
DR   eggNOG; KOG0799; Eukaryota.
DR   eggNOG; ENOG410XQ7M; LUCA.
DR   GeneTree; ENSGT00760000119183; -.
DR   HOGENOM; HOG000070086; -.
DR   HOVERGEN; HBG059443; -.
DR   InParanoid; Q86Y38; -.
DR   KO; K00771; -.
DR   OMA; IGTEWDA; -.
DR   OrthoDB; EOG091G020K; -.
DR   PhylomeDB; Q86Y38; -.
DR   TreeFam; TF315534; -.
DR   BioCyc; MetaCyc:HS02509-MONOMER; -.
DR   BRENDA; 2.4.2.26; 2681.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   SignaLink; Q86Y38; -.
DR   UniPathway; UPA00755; -.
DR   UniPathway; UPA00756; -.
DR   ChiTaRS; XYLT1; human.
DR   GeneWiki; XYLT1; -.
DR   GenomeRNAi; 64131; -.
DR   PRO; PR:Q86Y38; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000103489; -.
DR   CleanEx; HS_XYLT1; -.
DR   Genevisible; Q86Y38; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IEA:InterPro.
DR   GO; GO:0030158; F:protein xylosyltransferase activity; TAS:UniProtKB.
DR   GO; GO:0030206; P:chondroitin sulfate biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IEA:UniProtKB-UniPathway.
DR   InterPro; IPR003406; Glyco_trans_14.
DR   InterPro; IPR024448; XylT.
DR   Pfam; PF02485; Branch; 1.
DR   Pfam; PF12529; Xylo_C; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Dwarfism; Endoplasmic reticulum; Glycoprotein;
KW   Glycosyltransferase; Golgi apparatus; Membrane; Polymorphism;
KW   Reference proteome; Secreted; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN         1    959       Xylosyltransferase 1.
FT                                /FTId=PRO_0000191400.
FT   TOPO_DOM      1     17       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     18     38       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     39    959       Lumenal. {ECO:0000255}.
FT   CARBOHYD    226    226       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    421    421       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    777    777       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT     115    115       A -> S (in PXE; acts as a modifier of
FT                                disease severity; results in higher serum
FT                                xylosyltransferase activity;
FT                                dbSNP:rs61758388).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071271.
FT   VARIANT     325    325       P -> R (in dbSNP:rs28709752).
FT                                /FTId=VAR_049324.
FT   VARIANT     406    406       R -> W (in dbSNP:rs201009902).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071272.
FT   VARIANT     481    481       R -> W (in DBQD2; loss of predominance of
FT                                Golgi localization in mutant cells; DCN
FT                                in cell culture supernatant demonstrates
FT                                glycosylation differences between patient
FT                                and control cells; dbSNP:rs587777366).
FT                                {ECO:0000269|PubMed:23982343}.
FT                                /FTId=VAR_071273.
FT   VARIANT     598    598       R -> C (in DBQD2; dbSNP:rs587777367).
FT                                {ECO:0000269|PubMed:24581741}.
FT                                /FTId=VAR_071274.
FT   VARIANT     665    665       T -> M (in dbSNP:rs79030430).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071275.
FT   VARIANT     766    766       P -> A (in dbSNP:rs12325439).
FT                                /FTId=VAR_049325.
FT   VARIANT     839    839       V -> I (in dbSNP:rs7200466).
FT                                /FTId=VAR_049326.
FT   VARIANT     892    892       R -> Q (in dbSNP:rs35309694).
FT                                /FTId=VAR_049327.
FT   MUTAGEN     257    257       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     276    276       C->A: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     285    285       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     301    301       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     314    314       D->G: No effect.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     316    316       D->G: No effect.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     471    471       C->A: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     542    542       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     561    561       C->A: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     563    563       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     572    572       C->A: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     574    574       C->A: Strongly reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     675    675       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     745    745       D->E: No effect.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     745    745       D->G: Abolishes enzyme activity but does
FT                                not affect UDP-binding.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     746    746       W->D,N,G: Strongly reduced enzyme
FT                                activity but does not affect UDP-binding.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     747    747       D->G,E: Reduced enzyme activity but does
FT                                not affect UDP-binding.
FT                                {ECO:0000269|PubMed:15294915}.
FT   MUTAGEN     920    920       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     927    927       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
FT   MUTAGEN     933    933       C->A: No effect.
FT                                {ECO:0000269|PubMed:15461586}.
SQ   SEQUENCE   959 AA;  107569 MW;  056FC3F66EFD4D81 CRC64;
     MVAAPCARRL ARRSHSALLA ALTVLLLQTL VVWNFSSLDS GAGERRGGAA VGGGEQPPPA
     PAPRRERRDL PAEPAAARGG GGGGGGGGGG RGPQARARGG GPGEPRGQQP ASRGALPARA
     LDPHPSPLIT LETQDGYFSH RPKEKVRTDS NNENSVPKDF ENVDNSNFAP RTQKQKHQPE
     LAKKPPSRQK ELLKRKLEQQ EKGKGHTFPG KGPGEVLPPG DRAAANSSHG KDVSRPPHAR
     KTGGSSPETK YDQPPKCDIS GKEAISALSR AKSKHCRQEI GETYCRHKLG LLMPEKVTRF
     CPLEGKANKN VQWDEDSVEY MPANPVRIAF VLVVHGRASR QLQRMFKAIY HKDHFYYIHV
     DKRSNYLHRQ VLQVSRQYSN VRVTPWRMAT IWGGASLLST YLQSMRDLLE MTDWPWDFFI
     NLSAADYPIR TNDQLVAFLS RYRDMNFLKS HGRDNARFIR KQGLDRLFLE CDAHMWRLGD
     RRIPEGIAVD GGSDWFLLNR RFVEYVTFST DDLVTKMKQF YSYTLLPAES FFHTVLENSP
     HCDTMVDNNL RITNWNRKLG CKCQYKHIVD WCGCSPNDFK PQDFHRFQQT ARPTFFARKF
     EAVVNQEIIG QLDYYLYGNY PAGTPGLRSY WENVYDEPDG IHSLSDVTLT LYHSFARLGL
     RRAETSLHTD GENSCRYYPM GHPASVHLYF LADRFQGFLI KHHATNLAVS KLETLETWVM
     PKKVFKIASP PSDFGRLQFS EVGTDWDAKE RLFRNFGGLL GPMDEPVGMQ KWGKGPNVTV
     TVIWVDPVNV IAATYDILIE STAEFTHYKP PLNLPLRPGV WTVKILHHWV PVAETKFLVA
     PLTFSNRQPI KPEEALKLHN GPLRNAYMEQ SFQSLNPVLS LPINPAQVEQ ARRNAASTGT
     ALEGWLDSLV GGMWTAMDIC ATGPTACPVM QTCSQTAWSS FSPDPKSELG AVKPDGRLR
//
